Quality | 2019.03.27
IQN Path Selects SeraCare Life Sciences for First-Ever Tumor Mutational Burden External Quality Assessment Program
MILFORD, Mass. and LUXEMBOURG, March 27, 2019 /PRNewswire/ -- SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, announced today their successful selection as a technology partner in support of the first ever...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]essment-program-300819450.html
